These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

812 related articles for article (PubMed ID: 30278319)

  • 1. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
    Zheng W; Zhou YL; Wang CY; Lan XF; Ning YP
    J Affect Disord; 2023 Aug; 334():145-151. PubMed ID: 37160235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychopharmacol; 2019 Apr; 33(4):494-501. PubMed ID: 30789302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Lan XF; Zhang B; Ning YP
    J Affect Disord; 2020 Oct; 275():38-43. PubMed ID: 32658821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
    Zhan Y; Zhang B; Zhou Y; Zheng W; Liu W; Wang C; Li H; Chen L; Yu L; Walter M; Li M; Li MD; Ning Y
    J Affect Disord; 2019 May; 251():205-212. PubMed ID: 30927581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.
    Wang C; Lan X; Liu W; Zhan Y; Zheng W; Chen X; Liu G; Mai S; Lu H; McIntyre RS; Zhou Y; Ning Y
    Transl Psychiatry; 2024 Aug; 14(1):324. PubMed ID: 39107286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
    Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
    J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis.
    Wang M; Zhang B; Zhou Y; Wang C; Zheng W; Liu W; Zhan Y; Lan X; Ning Y
    Pharmacol Rep; 2021 Apr; 73(2):594-603. PubMed ID: 33387333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between depression subtypes and response to repeated-dose intravenous ketamine.
    Wang C; Zhou Y; Zheng W; Liu W; Zhan Y; Li H; Chen L; Zhang B; Walter M; Li M; Li MD; Ning Y
    Acta Psychiatr Scand; 2019 Nov; 140(5):446-457. PubMed ID: 31483855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
    Ballard ED; Luckenbaugh DA; Richards EM; Walls TL; Brutsché NE; Ameli R; Niciu MJ; Vande Voort JL; Zarate CA
    J Psychiatr Res; 2015 Sep; 68():68-73. PubMed ID: 26228403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study.
    Wilkowska A; Włodarczyk A; Gałuszko-Węgielnik M; Wiglusz MS; Cubała WJ
    Neuropsychiatr Dis Treat; 2021; 17():2637-2646. PubMed ID: 34421299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do the dissociative side effects of ketamine mediate its antidepressant effects?
    Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
    J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
    DiazGranados N; Ibrahim LA; Brutsche NE; Ameli R; Henter ID; Luckenbaugh DA; Machado-Vieira R; Zarate CA
    J Clin Psychiatry; 2010 Dec; 71(12):1605-11. PubMed ID: 20673547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study.
    Liu W; Zhou Y; Wang C; Zheng W; Zhan Y; Lan X; Zhang B; Li H; Chen L; Li M; Ning Y
    J Affect Disord; 2020 Jun; 271():1-8. PubMed ID: 32312692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
    aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
    Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.